Securities code: Jinghua Pharmaceutical Group Co.Ltd(002349) securities abbreviation: Jinghua Pharmaceutical Group Co.Ltd(002349) Announcement No.: 2022010 Jinghua Pharmaceutical Group Co.Ltd(002349)
Announcement on abnormal fluctuations in stock trading
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and are responsible for any false information in the announcement
Be liable for records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
Jinghua Pharmaceutical Group Co.Ltd(002349) (hereinafter referred to as “the company”) stock (Stock Code: Jinghua Pharmaceutical Group Co.Ltd(002349) , stock abbreviation: Jinghua Pharmaceutical Group Co.Ltd(002349) ) on March 16, 2022, March 17, 2022 and March 18, 2022, the cumulative deviation of the closing price increase exceeds 20%. According to the relevant regulations of Shenzhen Stock Exchange, it belongs to the situation of abnormal fluctuation of stock trading.
2、 Description of the company’s concern and verification
In view of the abnormal fluctuation of the company’s stock trading, the board of directors of the company has verified the relevant problems, and now the relevant information is explained as follows:
1. The information disclosed by the company in the early stage does not need to be corrected or supplemented.
2. The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently.
3. The company, the controlling shareholder and the actual controller have no major events that should be disclosed but not disclosed about the company, or major events in the planning stage.
4. During the period of stock change, the controlling shareholders of the company did not buy or sell the company’s shares.
5. The company has no other circumstances in violation of the provisions on fair information disclosure.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that the company does not have any matters that should be disclosed but not disclosed in accordance with the relevant provisions such as the Listing Rules of Shenzhen Stock Exchange; The board of directors has not been informed of the information that should be disclosed by the company according to the Listing Rules of Shenzhen Stock Exchange and other relevant provisions, which has a great impact on the trading price of the company’s shares; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
2. The information disclosure media designated by the company are securities times and http://www.cn.info.com.cn, All information publicly disclosed by the company is published in the above designated media
Securities code: Jinghua Pharmaceutical Group Co.Ltd(002349) securities abbreviation: Jinghua Pharmaceutical Group Co.Ltd(002349) Announcement No.: 2022010 announcement shall prevail.
3. The company’s 2021 annual report will be disclosed on March 30, 2022. Investors are reminded to pay attention to investment risks.
4. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please invest rationally and pay attention to risks.
It is hereby announced.
Jinghua Pharmaceutical Group Co.Ltd(002349) board of directors March 21, 2022
